BMY vs JNJ
BMY: A leading biopharmaceutical innovator focused on discovering and delivering life-changing medicines to address serious illnesses globally. JNJ: Johnson & Johnson is a global leader in innovative pharmaceuticals and advanced medical technology dedicated to addressing the world's most complex health challenges.
Side-by-side fundamentals
| Metric | BMY | JNJ | Edge |
|---|---|---|---|
| Price as of 2026-08-24 close | $67.28 | $273.04 | |
| Market cap as of 2026-08-25 | $137.4B | $658.0B | |
| P/E as of 2026-08-25 | 14.21 | 29.93 | BMY lower |
| PEG as of 2026-08-25 | -8.67 | 3.39 | BMY lower |
| Net margin as of 2026-08-25 | +18.9% | +21.5% | JNJ higher |
| Gross margin as of 2026-08-25 | +71.7% | +68.0% | BMY higher |
| Operating margin as of 2026-08-25 | +25.5% | +25.7% | JNJ higher |
| ROE as of 2026-08-25 | +46.8% | +25.7% | BMY higher |
| ROA as of 2026-08-25 | +10.3% | +10.6% | JNJ higher |
| Debt / equity as of 2026-08-25 | 1.93 | 0.58 | JNJ lower |
| Revenue growth (YoY) as of 2026-08-25 | +3.1% | +8.1% | JNJ higher |
| Revenue CAGR (3y) SEC XBRL | +1.4% | +6.2% | JNJ higher |
| Dividend yield as of 2026-08-25 | +4.6% | +3.1% | BMY higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-08-25 | 0.18 | 0.20 | |
| 1-year return as of 2026-08-24 close | +40.4% | +52.3% | JNJ higher |
Fundamentals: market data, as of 2026-08-25. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.